Skip to content
DraconiticResearch
Search Sources API
174,684 studies31 sourcesUpdated 50 min ago
Peer-reviewedCC BY 4.0JAMA Network Open

GLP-1 Receptor Agonists and Obesity-Related Cancer by Diabetes Severity

  • Jesús Gibran Hernández-Pérez1,2
  • Omer Abdelgadir1
  • Luisa Torres-Sánchez2
  • Jing Chen3
  • Jaime P. Almandoz3
  • Lindsay G. Cowell1,4
  • Sarah E. Messiah1,4,5,6
  • David S. Lopez1,4
6 affiliations
  1. 1Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas
  2. 2Center for Population Health Research, National Institute of Public Health, Cuernavaca, Morelos, Mexico
  3. 3Department of Internal Medicine, Division of Endocrinology, University of Texas Southwestern Medical Center, Dallas
  4. 4Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas
  5. 5Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas
  6. 6Children’s Health System of Texas, Dallas
Open at sourceDOICite

Abstract

This cohort study examines the associations between glucagon-like peptide-1 receptor agonist (GLP-1 RA) initiation and obesity-related cancer incidence across active comparators and baseline type 2 diabetes severity.

Related

  1. Insights from multi-omics on GLP-1 receptor agonists in type 2 diabetes and obesity
    Asma A. Elashi, Laila Hedaya, Viviana Maggio +3
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textEndocrinology & metabolismCrossrefPMC
  2. Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Cardiovascular Events and Death in Treated Serious Mental Illness, Type 2 Diabetes, and Obesity
    Samuel B. Governor, David M. Dávila‐García, Eliut Rivera‐Segarra +7
    Journal of the American Heart AssociationPeer-reviewedCC BY-NC-NDEndocrinology & metabolismCrossref
  3. Neuropsychiatric Safety of GLP-1 Receptor Agonists and Tirzepatide in Adults with Type 2 Diabetes Mellitus or Obesity.
    Het Tushar Jani, Helisse Levine, Abhiraj Patel +2
    Rambam Maimonides medical journalPeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
  4. Modern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists
    Dorota Bartkowiak, Barlomiej Jakubczyk, Adam Lasota +7
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Economic evaluation of SGLT2 inhibitors and GLP-1 receptor agonists in Thai patients with type 2 diabetes and established atherosclerotic cardiovascular disease
    Tanawan Kongmalai, Natthakan Chitpim, Varalak Srinonprasert +2
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textEndocrinology & metabolismCrossref

Cite

BibTeXRIS
BibTeX
@article{hernandezperez2026glp1,
  title = {{GLP-1 Receptor Agonists and Obesity-Related Cancer by Diabetes Severity}},
  author = {Jesús Gibran Hernández-Pérez and Omer Abdelgadir and Luisa Torres-Sánchez and Jing Chen and Jaime P. Almandoz and Lindsay G. Cowell and Sarah E. Messiah and David S. Lopez},
  journal = {JAMA Network Open},
  year = {2026},
  month = nov,
  doi = {10.1001/jamanetworkopen.2026.41869},
  url = {https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2856231},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - GLP-1 Receptor Agonists and Obesity-Related Cancer by Diabetes Severity
AU  - Jesús Gibran Hernández-Pérez
AU  - Omer Abdelgadir
AU  - Luisa Torres-Sánchez
AU  - Jing Chen
AU  - Jaime P. Almandoz
AU  - Lindsay G. Cowell
AU  - Sarah E. Messiah
AU  - David S. Lopez
PY  - 2026
DA  - 2026/11/03
JO  - JAMA Network Open
DO  - 10.1001/jamanetworkopen.2026.41869
UR  - https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2856231
AB  - This cohort study examines the associations between glucagon-like peptide-1 receptor agonist (GLP-1 RA) initiation and obesity-related cancer incidence across active comparators and baseline type 2 diabetes severity.
SN  - 2574-3805
ER  -